Europe
Heidelberg, Germany-based Boehringer Ingelheim has exercised its option to buy an EMBL Ventures portfolio company, ViraTherapeutics. This follows a collaboration and option deal inked between the two companies in August 2016.
Although Hurricane Florence has been downgraded to a Category 2, the massive storm has the potential to dump enough rain to produce catastrophic flooding across the Carolinas. Despite the downgrade, Pfizer is taking no chances and will close its North Carolina injectables plant ahead of the storm.
Paris-based Sanofi announced it is refocusing two of its international business units. The goal is to create more focus on mature markets and emerging markets.
Galapagos NV announced today that it intends to offer and sell, subject to market and other conditions, $300 million of its ordinary shares in the form of American Depositary Shares (ADSs) in a U.S. public offering.
Galapagos NV and MorphoSys AG announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) in connection with the worldwide, exclusive license agreement with Novartis Pharma AG, entered into on July 19, 2018, for the development and commercialization of their joint program MOR106 (the Collaboration Agreement).
IPH5401 is a first-in-class antibody targeting the C5a receptor expressed on subsets of myeloid-derived suppressor cells (MDSC) and neutrophils in the tumor microenvironment
Founder and Chairman, Dr David Taylor, of Guildford based MR Solutions has been shortlisted as an Innovation Entrepreneur of the Year for London and the South East in the 2018 NatWest Great British Entrepreneur Awards.
NHS patients to benefit from Europe’s first full access deal on breakthrough CAR-T therapy.
IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics
Plasticell Ltd has announced that it has been contracted by the Ministry of Defence (MoD) in a pilot programme to develop regenerative medicines for the treatment of injuries resulting from combat or terrorism.
PRESS RELEASES